Cargando…

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

BACKGROUND: Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade ≥2 immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear. METHODS: All adverse drug reactions involving at least one ICI reported up to December 31, 2019 were extracted from the French p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allouchery, Marion, Lombard, Thomas, Martin, Mickael, Rouby, Franck, Sassier, Marion, Bertin, Celia, Atzenhoffer, Marina, Miremont-Salame, Ghada, Perault-Pochat, Marie-Christine, Puyade, Mathieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768965/ https://www.ncbi.nlm.nih.gov/pubmed/33428586 http://dx.doi.org/10.1136/jitc-2020-001622

Ejemplares similares

Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database
por: Martin, Mickaël, et al.
Publicado: (2022)

Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
por: Hwang, Bin-Jin, et al.
Publicado: (2022)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
por: Mao, Chenkai, et al.
Publicado: (2022)

Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors
por: Reil, Katherine A, et al.
Publicado: (2023)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

PKR induces TGF-β and limits oncolytic immune therapy
por: Hong, Bangxing, et al.
Publicado: (2023)

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
por: Allouchery, Marion, et al.
Publicado: (2022)

Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3α Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity
por: Wang, Jin-Yan, et al.
Publicado: (2022)

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
por: Maslov, Diana V, et al.
Publicado: (2021)

Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
por: Groeneveldt, Christianne, et al.
Publicado: (2022)

Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis
por: Wang, Duo, et al.
Publicado: (2023)

Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2023)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
por: Hu, Jianjun, et al.
Publicado: (2022)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
por: Huang, Feng-Ying, et al.
Publicado: (2020)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
por: Müller, Louise M E, et al.
Publicado: (2021)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
por: Ager, Casey R, et al.
Publicado: (2021)

Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry
por: Nguyen, Teresa T, et al.
Publicado: (2022)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020)

Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer
por: Bari, Elia, et al.
Publicado: (2023)

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
por: Monge, Cecilia, et al.
Publicado: (2023)

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
por: Jhawar, Sachin R, et al.
Publicado: (2023)

New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)

Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
por: Sabree, Shakoora A, et al.
Publicado: (2021)

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma
por: Leb-Reichl, Victoria M, et al.
Publicado: (2021)

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
por: Munoz, Luis Enrique, et al.
Publicado: (2021)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
por: Anfray, Clément, et al.
Publicado: (2021)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
por: Beasley, Georgia M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tjkfhog1i99cq5bkht3q5k24b6